Ellagic Acid and Sennoside B Inhibit Osteosarcoma Cell Migration, Invasion and Growth by Repressing the Expression of C-Jun.

Wei Xu,Jinjin Xu,Ting Wang,Weibo Liu,Haifeng Wei,Xinghai Yang,Wangjun Yan,Wang Zhou,Jianru Xiao
DOI: https://doi.org/10.3892/ol.2018.8712
2018-01-01
Oncology Letters
Abstract:Osteosarcoma is a mesenchymally derived, high-grade bone sarcoma that is the most frequently diagnosed primary malignant bone tumor. Today, chemoprevention is regarded as a promising and realistic approach in the prevention of human cancer. Previous studies have suggested ellagic acid (EA) and Sennoside B have potential in this regard. The aim of the present study was to elucidate the anti-osteosarcoma effects of EA and Sennoside B by using Saos-2 and MG63 osteosarcoma cells. It was identified that EA or Sennoside B treatment could inhibit the growth, migration and invasion of the cells, and induce G1 cell cycle arrest by repressing the transcription of c-Jun. These results may provide a cellular basis for the application of EA or Sennoside B in the treatment of patients with osteosarcoma.
What problem does this paper attempt to address?